JP2014522414A5 - - Google Patents

Download PDF

Info

Publication number
JP2014522414A5
JP2014522414A5 JP2014514910A JP2014514910A JP2014522414A5 JP 2014522414 A5 JP2014522414 A5 JP 2014522414A5 JP 2014514910 A JP2014514910 A JP 2014514910A JP 2014514910 A JP2014514910 A JP 2014514910A JP 2014522414 A5 JP2014522414 A5 JP 2014522414A5
Authority
JP
Japan
Prior art keywords
hemodialysis
composition
dialysis
serum phosphorus
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014514910A
Other languages
English (en)
Japanese (ja)
Other versions
JP5982473B2 (ja
JP2014522414A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/041759 external-priority patent/WO2012170955A1/en
Publication of JP2014522414A publication Critical patent/JP2014522414A/ja
Publication of JP2014522414A5 publication Critical patent/JP2014522414A5/ja
Application granted granted Critical
Publication of JP5982473B2 publication Critical patent/JP5982473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014514910A 2011-06-08 2012-06-08 血清リンを調節するための治療剤 Active JP5982473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494874P 2011-06-08 2011-06-08
US61/494,874 2011-06-08
PCT/US2012/041759 WO2012170955A1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus

Publications (3)

Publication Number Publication Date
JP2014522414A JP2014522414A (ja) 2014-09-04
JP2014522414A5 true JP2014522414A5 (https=) 2015-07-23
JP5982473B2 JP5982473B2 (ja) 2016-08-31

Family

ID=46321485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014514910A Active JP5982473B2 (ja) 2011-06-08 2012-06-08 血清リンを調節するための治療剤

Country Status (23)

Country Link
US (1) US8969299B2 (https=)
EP (1) EP2717896B1 (https=)
JP (1) JP5982473B2 (https=)
KR (1) KR102057508B1 (https=)
CN (1) CN103857405B (https=)
AU (1) AU2012267470C1 (https=)
BR (1) BR112013031539A2 (https=)
CA (1) CA2837445C (https=)
CY (1) CY1118430T1 (https=)
DK (1) DK2717896T3 (https=)
ES (1) ES2607986T3 (https=)
HR (1) HRP20161566T1 (https=)
HU (1) HUE032087T2 (https=)
LT (1) LT2717896T (https=)
MX (1) MX337613B (https=)
PL (1) PL2717896T3 (https=)
PT (1) PT2717896T (https=)
RS (1) RS55503B1 (https=)
RU (1) RU2612912C2 (https=)
SG (1) SG195290A1 (https=)
SI (1) SI2717896T1 (https=)
SM (2) SMT201700081T1 (https=)
WO (1) WO2012170955A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
MA38724B1 (fr) 2013-06-28 2017-11-30 Amgen Inc Formulation liquide stable d'amg 416 (velcalcétide)
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
WO2021115272A1 (zh) * 2019-12-09 2021-06-17 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
EP4212542A4 (en) * 2020-09-10 2024-08-28 Shaanxi Micot Technology Co., Ltd. BISPECIFIC FUSION POLYPEPTIDE COMPOUND

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
AU9131091A (en) 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995006056A1 (en) 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
AU7895601A (en) 2000-07-18 2002-01-30 Bone Care Int Inc Stabilized 1alpha-hydroxy vitamin d
US20080249016A1 (en) 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
US20030091640A1 (en) 2001-02-08 2003-05-15 Srinivasan Ramanathan Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
AU2002247724B2 (en) 2001-02-23 2008-02-07 Polyphor Ltd. Template-fixed peptidomimetics with antimicrobial activity
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
US20040018976A1 (en) 2002-05-14 2004-01-29 Feder John N. Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof
WO2004093821A2 (en) 2003-04-22 2004-11-04 Hawaii Biotech, Inc. Treatment of anthrax infection using inhibitors of lethal factor protease activity
EP1680446B1 (en) 2003-11-05 2007-10-31 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
CA2549052A1 (en) 2003-12-11 2005-06-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific antagonists of protein kinase c
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
WO2007027510A2 (en) 2005-08-30 2007-03-08 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
CA2989778C (en) 2007-01-19 2020-06-30 Kai Pharmaceuticals, Inc. Method of modifying peptide compositions
WO2009046220A2 (en) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
US8999932B2 (en) 2009-07-29 2015-04-07 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Similar Documents

Publication Publication Date Title
HUE029677T2 (hu) Készítmények centrálisan mediált émelygés és hányás kezelésére
JP2015502346A5 (https=)
JP6381761B2 (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
JP2016518387A5 (https=)
JP2017513882A5 (https=)
JP2014502641A5 (https=)
JP2015520188A5 (https=)
JP2010518079A5 (https=)
WO2007081975A2 (en) Method of treating multiple sclerosis
JP2014522414A5 (https=)
JP2014506583A5 (https=)
JP2016516016A5 (https=)
JP2013521303A5 (https=)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2024516363A (ja) リボシクリブ及びアムセネストラントを含む組み合わせ
FI3518932T3 (fi) Eturauhassyövän hoito
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2020502261A5 (https=)
JP2014513705A (ja) 進行性固形腫瘍の治療方法
JP2018531605A5 (https=)
JP2015522077A5 (https=)
Kumar et al. Weekly MLN9708, an investigational oral proteasome inhibitor, in relapsed/refractory multiple myeloma: results from a phase I study after full enrollment
JP6743001B2 (ja) シス−クロミフェンを用いたアンドロゲン除去療法によって生じるホットフラッシュ及び骨量減少の治療
JP2016515137A5 (https=)
JP2014530204A5 (https=)